1)Amarenco P, Labreuche J:Lipid management in the prevention of stroke;Reviewed and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453-463, 2009
2)Cholesterol Treatment Trialists'(CTT)Collaboration:Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 376:1670-1681, 2010
3)Caterina RD, et al:Cholesterol-lowering interventions and stroke;insight from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 55:198-211, 2010
4)Sever PS, et al:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial─Lipid Lowering Arm(ASCOT-LLA). Lancet 361:1149-1158, 2003
5)Colhoun HM, et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS). Lancet 364:685-696, 2004
6)Nakamura H, et al:Primary prevention of cardiovascular disease with pravastation in Japan(MEGA Study);A prospective randomised controlled trial. Lancet 368:1155-1163, 2006
7)Uchiyama S, et al:Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese atients with hypercholesterolemia:Analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci 284:72-76, 2009
8)Amarenco P, et al:Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack:the Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL)trial. Stroke 38:3198-3204, 2007
9)Tanaka K, et al:Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients:subanalysis of the JELIS trial. Stroke 39:2052-2058, 2008